Malbin retires from CTFA
This article was originally published in The Rose Sheet
Executive Summary
VP Public Affairs Irene Malbin will retire after 17 years of service with the association, effective May 31, The Cosmetic, Toiletry and Fragrance Association reports May 18. A replacement has not been chosen. During her tenure, Malbin has been incremental in reporting CTFA's work to the public. She also developed the association's "Work Your Image!" program which offers advice for women on job interviewing and professional appearance, and helped plan and execute CTFA's 100 anniversary events, spearheaded CTFA's sponsorship of the PBS series "Mystery of the Senses" and served as public affairs counsel for CTFA Foundation's "Look Good...Feel Better" program. Before joining CTFA, Malbin worked in public affairs for the National Soft Drink Association and FDA...
You may also be interested in...
How China Inc. Aims To Take Over Cell Therapy Dominance
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
QUOTED. 14 August 2020. Jonathan Walker.
Updated guidance from England’s National Institute for Health and Care Excellence says two neurostimulation systems for treatment-resistant depression and epilepsy should only be used under special conditions. See what LivaNova’s VP of difficult-to-treat depression, Jonathan Walker, said about it here.
Samsung BioLogics’ 'Super Plant' Reflects Robust Global COVID-19 R&D
Samsung BioLogics’ construction of a fourth, large-scale manufacturing plant reflects increasing orders amid robust global COVID-19 R&D activities and further cements the Korean firm's position as the world's biggest contract biologics producer.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: